Consistent with the understanding of comorbidity-infl ammation relationship, concomitant diseases and especially metabolic comorbidities are thought to stimulate development severity heart failure preserved ejection fraction through a cascade mechanisms supporting systemic tissue infl leading myocardial fi brosis. Recently, new experimental clinical evidence has emerged that enhances validity veri...

the effect of four inhibitors on calmalulin (cum) were studied by a ftuorescence and ultraviolet techniques. four compounds in - ( 6 - aminohexyt) 5-chloro - i - napthalenesulphonamide] (w-7), 1 - [ bis - (4 - chtorophenyt) methyl] - 3 - [2, 4-dichloro - β - ( 2 , 4 - dichlorobenzyloxyl) phenethyt] imidazolium chloride (r24571), trifluoperazine (tfp) , thiodiphenylamide chloride (tdpac) showed ...

The role of phosphodiesterase in glucagon resistance of large adipocytes was investigated. A comparison was made of phosphodiesterase activities of homogenates prepared from isolated small (mean diameter approximately 45 micro m) and large (mean diameter approximately 78 micro m) adipocytes, using various concentrations (5 x 10(-4) to 1 x 10(-7) M) of 3',5'-cAMP. Kinetic analyses revealed two d...

Little is known about of the comparative cardiac lusitropic and coronary vasoactive effects of type III phosphodiesterase inhibitors independent of their systemic circulatory effects. We hypothesized that phosphodiesterase inhibitors have dissimilar concentration-dependent effects on cardiac function and metabolism and that their coronary vasodilatory effects are solely dependent on flow autore...

1. A new assay procedure has been devised for measurement of the Ca(2+)-activated polyphosphoinositide phosphodiesterase (phosphatidylinositol polyphosphate phosphodiesterase) activity of erythrocyte ghosts. The ghosts are prepared from cells previously incubated with [(32)P]P(i). They are incubated under appropriate conditions for activation of the phosphodiesterase and the released (32)P-labe...